Buy, Sell or Hold: BioMarin Pharmaceutical (BMRN-Q)

Home

Daily Stock Opinions and Ratings

BioMarin Pharmaceutical (BMRN-Q)

NASDAQ:BMRN

57.28

0.12 (0.21%) 1d

Nervous markets await Nvidia

Most recent Opinions go here

Be up to date, don’t miss your chance.

DON'T BUY

The orphan drug model no longer works.

Showing 1 to 1 of 1 entries

BioMarin Pharmaceutical(BMRN-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for BioMarin Pharmaceutical is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

BioMarin Pharmaceutical(BMRN-Q) Frequently Asked Questions

What is BioMarin Pharmaceutical stock symbol?

BioMarin Pharmaceutical is a American stock, trading under the symbol BMRN-Q on the NASDAQ (BMRN). It is usually referred to as NASDAQ:BMRN or BMRN-Q

Is BioMarin Pharmaceutical a buy or a sell?

In the last year, 1 stock analyst published opinions about BMRN-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for BioMarin Pharmaceutical.

Is BioMarin Pharmaceutical a good investment or a top pick?

BioMarin Pharmaceutical was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for BioMarin Pharmaceutical.

Why is BioMarin Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is BioMarin Pharmaceutical worth watching?

In the last year, there was no coverage of BioMarin Pharmaceutical published on Stockchase.

What is BioMarin Pharmaceutical stock price?

On 2025-06-12, BioMarin Pharmaceutical (BMRN-Q) stock closed at a price of $57.28.

Most Recent Experts

Stan Wong

Private Wealth Management, ScotiaMcleod

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.